IHP Co-Invest IV-B, LP is a small but institutionally connected medical-device private-equity vehicle managed within the InnovaHealth Partners organization. Its October 2, 2026 Form D reports $3.16 million sold to five investors, an indefinite offering, no sales commissions or finder's fees and no fixed minimum investment. The simple average commitment is approximately $632,000 per investor, although actual allocations may vary, and the fund relies on Section 3(c)(7), meaning the economic reality is much more exclusive than the $0 minimum field suggests. The strongest positive is that the adviser is unusually easy to verify: InnovaHealth Partners, LP is an SEC-registered investment adviser under CRD 297788 and SEC file 801-126204, effective since July 2022, and its August 2026 Form ADV explicitly includes IHP Co-Invest IV-B among the firm's private funds. InnovaHealth reported roughly $301 million of regulatory assets under management for its 2025 fiscal year, all associated with pooled investment vehicles, while the same ADV identifies a wider family of IHP Co-Invest I through VI vehicles. This makes IV-B very different from a standalone Form D whose management structure cannot be independently reconstructed.
The biggest issue in the filing is timing. IV-B states that its first sale occurred on November 18, 2025, but the only Form D presently visible for this CIK was filed on October 2, 2026, more than ten months later. SEC guidance says an issuer relying on Regulation D generally must file Form D no later than 15 calendar days after the first sale, where first sale means the first investor becomes irrevocably contractually committed. That makes the chronology worthy of direct explanation from InnovaHealth. It should not, however, be exaggerated into a claim that the offering automatically lost its exemption: the SEC expressly says Form D filing is a Rule 503 requirement but is not itself a condition to the availability of Rule 506(b), and late issuers are instructed to file as soon as practicable. An additional detail makes the chronology more interesting rather than less: InnovaHealth's August 5, 2026 Form ADV already disclosed IHP Co-Invest IV-B as a private fund before the October Form D appeared. In other words, this was not a vehicle that suddenly came into existence on October 2. The public adviser record already recognized it. Investors should therefore ask whether an earlier Form D was omitted, filed under another vehicle, delayed administratively, or simply submitted late, because the public dates do not align with the normal 15-day filing timetable.
The structure also deserves more attention than the $3.16 million headline. InnovaHealth's latest ADV does not show IV-B as an isolated vehicle; it sits beside IHP Co-Invest IV and IV-A and a broader sequence of IHP co-investment funds. The main IHP Co-Invest IV vehicle reports approximately $15.7 million of gross assets and 16 beneficial owners in the latest adviser disclosure, while IV-A is also separately reported. This strongly suggests that IV-B is a sleeve or parallel co-investment vehicle connected to a larger transaction architecture rather than a conventional diversified flagship fund. The exact underlying portfolio company, however, is not identified in the public Form D, and that prevents outsiders from determining whether IV-B owns Route 92 Medical, Materna Medical, Channel Medsystems, Monteris Medical, Koelis or another InnovaHealth-backed medical-device business. InnovaHealth's current portfolio is concentrated in technologies such as neurointervention, women's pelvic health, neurosurgery and other specialist medical devices, and several portfolio companies raised fresh capital during 2026, including Route 92 Medical and Materna. None of those facts is sufficient to assign one of those companies to IV-B. Investors need the co-investment memorandum to establish exactly which company, security and financing round sit beneath the vehicle. That matters because a five-investor co-investment fund can be far more concentrated than InnovaHealth's broader portfolio, even when the sponsor itself manages many healthcare assets.
The manager history provides both a positive and an additional diligence layer. InnovaHealth says its team worked together for more than 15 years at HealthpointCapital, which it describes as its predecessor firm, and current founders Mortimer "Tim" Berkowitz III and John McCormick have decades of medical-device private-equity experience. Berkowitz's public board history includes companies such as Alphatec, while Ariella Golomb has direct board involvement with current InnovaHealth portfolio companies including Materna and Route 92 Medical. Searching only the InnovaHealth name would therefore miss a large portion of the team's investment history, including older HealthpointCapital transactions and litigation. In the 2010-2014 period, HealthpointCapital and Berkowitz were among defendants in shareholder and commercial litigation connected with Alphatec's acquisition of Scient'x; public SEC records show that derivative litigation eventually proceeded toward settlement, while other claims were contested or dismissed at various stages. Those matters substantially predate InnovaHealth and do not involve IHP Co-Invest IV-B, so they should not be presented as a current enforcement problem or as evidence of misconduct by this fund. They are still part of the predecessor-manager record that serious diligence should uncover rather than treating the 2017 InnovaHealth launch as the beginning of the principals' history.
Our assessment is therefore different from a typical "is this fund real" review. IHP Co-Invest IV-B has a strong regulatory identity trail: the SEC filing is verifiable, the fund is explicitly disclosed in its adviser's Form ADV, InnovaHealth is a genuine SEC-registered adviser, and the organization reports established auditing, administration and external marketing arrangements across its private-fund platform. The principal risks are instead the unexplained Form D timing, opacity around the exact co-investment asset, single-company concentration, medical-device regulatory and commercialization risk, and the economics created by multiple IV / IV-A / IV-B vehicles around what may be related investments. Investors should ask whether all parallel vehicles entered at the same valuation and security terms, how opportunities were allocated among the flagship fund and co-invest vehicles, whether any vehicle receives preferential rights or fees, and what management fee or carried-interest economics apply despite the Form D showing $0 sales commissions. Medical-device investing adds another layer because even technically strong products can depend on FDA clearance, clinical evidence, reimbursement, physician adoption and hospital purchasing cycles before producing a successful exit. The public record supports a credible and experienced manager, but it also leaves one unusually concrete compliance question unanswered: why did a Rule 506(b) vehicle reporting a November 2025 first sale wait until October 2026 for its visible Form D